Hot flashes have been reported in as many as 80% of men with prostate cancer treated with ADT. In men treated with ADT, endorphins may be reduced because of suppression of testosterone levels. This reduction in endorphins may mediate the process of lowering the thermoregulatory set point and ...
Prescribing a GnRH agonist is an example of androgen deprivation therapy, also known as ADT.Examples of GnRH agonists available today in the USA are: GnRH agonists are approved and used in the USA for palliative treatment in patients with advanced prostate cancer. The benefits of this type of ...
KlotzLaurenceNat Rev UrolNature Reviews UrologyLaurence Klotz. (2013) Prostate cancer: Intermittent ADT—tales from a 27-year odyssey. Nature Reviews Urology 10 , 372-374 /LaurenceKlotz. (2013) Prostate cancer: Intermittent ADT—tales from a 27-year odyssey. Nature Reviews Urology 10 , 372-374...
ADT is known to provide remission of the disease, best evidenced by a decline of prostate-specific antigen (PSA) in about 90% of patients.2After a mean time of 2–3 years, however, the disease progresses despite continuous hormonal manipulation. This type of cancer is known as castrate-resi...
[27]. The approved drugs used for ADT are abiraterone acetate and enzalutamide. The drugs used in chemotherapy include docetaxel, cabazitaxel, mitoxantrone, and radium-223, which are radioisotopes used for cancer treatment [28]. The drugs got approval from United States Food and Drug Administration...
Tumor flare as well as other complications caused by initial ADT drugs has led to the development of GnRH antagonists.48 Degarelix, a novel injectable GnRH-receptor antagonist, is one such drug that was recently approved by the FDA for patients with advanced prostate cancer. It does not cause ...
Astellas Pharma Korea said its prostate cancer treatment, Xtandi (ingredient: enzalutamide), received expanded approval from the Ministry of Food and Drug Safety (MFDS) on Tuesday.Under the expanded approval, adult patients with high-risk biochemical rec
ADT indicates androgen-deprivation therapy; CRPC, castration-resistant prostate cancer; FDA, US Food and Drug Administration; LHRH, luteinizing hormone-releasing hormone; PCa, prostate cancer; PSA, prostate-specific antigen. Source: Adapted with permission from Crawford ED, Flaig TW. Optimizing ...
More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all ...
Here, we describe a patient with high-risk prostate cancer treated by neoadjuvant intense ADT and surgery. Retrospective analysis of imaging and tissue data revealed that there were two potentially lethal-independent cancers present at baseline, and the two tumors responded differently and demonstrated ...